Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 491

1.

Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models.

Elekonawo FMK, Bos DL, Goldenberg DM, Boerman OC, Rijpkema M.

EJNMMI Res. 2019 Dec 11;9(1):108. doi: 10.1186/s13550-019-0580-z.

2.

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.

Huizing FJ, Garousi J, Lok J, Franssen G, Hoeben BAW, Frejd FY, Boerman OC, Bussink J, Tolmachev V, Heskamp S.

Sci Rep. 2019 Dec 11;9(1):18898. doi: 10.1038/s41598-019-54824-5.

3.

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.

van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E, Boerman OC, Jenniskens SF, Oyen WJG, Fütterer JJ, Mulders PFA.

Eur J Nucl Med Mol Imaging. 2019 Nov 25. doi: 10.1007/s00259-019-04613-z. [Epub ahead of print]

PMID:
31768601
4.

Additional information on "Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET".

Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, Moreau M, Bernhard C, Da Costa L, Dubois A, Goncalves V, Gustafsson M, Rijpkema M, Boerman O, Chambron JC, Heskamp S, Denat F.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):505-506. doi: 10.1007/s00259-019-04561-8. Epub 2019 Nov 9. No abstract available.

5.

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.

Derks YHW, Löwik DWPM, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, Lütje S, Heskamp S.

Theranostics. 2019 Sep 20;9(23):6824-6839. doi: 10.7150/thno.36739. eCollection 2019. Review.

6.

A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT.

Lobeek D, Bouwman FCM, Aarntzen EHJG, Molkenboer-Kuenen JDM, Flucke UE, Nguyen HL, Vikkula M, Boon LM, Klein W, Laverman P, Oyen WJG, Boerman OC, Terry SYA, Schultze Kool LJ, Rijpkema M.

J Nucl Med. 2020 Feb;61(2):270-275. doi: 10.2967/jnumed.119.231167. Epub 2019 Sep 13.

PMID:
31519800
7.

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.

Elekonawo FMK, Lütje S, Franssen GM, Bos DL, Goldenberg DM, Boerman OC, Rijpkema M.

EJNMMI Res. 2019 Sep 4;9(1):86. doi: 10.1186/s13550-019-0551-4.

8.

Measuring the Pancreatic β Cell Mass in Vivo with Exendin SPECT during Hyperglycemia and Severe Insulitis.

Joosten L, Brom M, Peeters H, Bos D, Himpe E, Bouwens L, Boerman O, Gotthardt M.

Mol Pharm. 2019 Sep 3;16(9):4024-4030. doi: 10.1021/acs.molpharmaceut.9b00728. Epub 2019 Aug 8.

PMID:
31345042
9.

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.

Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, Fracasso G, Colombatti M, Herrmann K, Boerman OC, Gotthardt M, Rijpkema M.

Theranostics. 2019 May 4;9(10):2924-2938. doi: 10.7150/thno.35274. eCollection 2019.

10.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

11.

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET.

Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, Moreau M, Bernhard C, Da Costa L, Dubois A, Goncalves V, Gustafsson M, Rijpkema M, Boerman O, Chambron JC, Heskamp S, Denat F.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1966-1977. doi: 10.1007/s00259-019-04343-2. Epub 2019 Jun 3.

12.

Monitoring 111In-labelled polyisocyanopeptide (PIC) hydrogel wound dressings in full-thickness wounds.

Op 't Veld RC, Joosten L, van den Boomen OI, Boerman OC, Kouwer P, Middelkoop E, Rowan AE, Jansen JA, Walboomers XF, Wagener FADTG.

Biomater Sci. 2019 Jul 1;7(7):3041-3050. doi: 10.1039/c9bm00661c. Epub 2019 May 22.

PMID:
31115398
13.

In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.

Lütje S, Franssen GM, Herrmann K, Boerman OC, Rijpkema M, Gotthardt M, Heskamp S.

J Nucl Med. 2019 Jul;60(7):1017-1022. doi: 10.2967/jnumed.118.218941. Epub 2019 Jan 17.

PMID:
30655329
14.

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.

Huizing FJ, Hoeben BAW, Franssen GM, Boerman OC, Heskamp S, Bussink J.

Mol Pharm. 2019 Feb 4;16(2):701-708. doi: 10.1021/acs.molpharmaceut.8b00950. Epub 2018 Dec 31.

15.

PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.

Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, Sandker GW, Thordardottir S, Cany J, Olive D, Bussink J, Boerman OC, Dolstra H, Aarntzen EHJG, Hobo WA.

Cancer Immunol Res. 2019 Jan;7(1):150-161. doi: 10.1158/2326-6066.CIR-18-0280. Epub 2018 Nov 20.

16.

Validation of 111In-Exendin SPECT for the Determination of the β-Cell Mass in BioBreeding Diabetes-Prone Rats.

Brom M, Joosten L, Frielink C, Peeters H, Bos D, van Zanten M, Boerman O, Gotthardt M.

Diabetes. 2018 Oct;67(10):2012-2018. doi: 10.2337/db17-1312. Epub 2018 Jul 25.

17.

Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma.

Odenthal J, Rijpkema M, Bos D, Wagena E, Croes H, Grenman R, Boerman O, Takes R, Friedl P.

Sci Rep. 2018 Jul 11;8(1):10467. doi: 10.1038/s41598-018-28059-9.

18.

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG, Mulders PFA.

Eur Urol. 2018 Sep;74(3):257-260. doi: 10.1016/j.eururo.2018.04.026. Epub 2018 May 3.

PMID:
29730017
19.

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.

Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, Oyen WJ, Langenhuijsen JF, Mulders PF.

Theranostics. 2018 Mar 8;8(8):2161-2170. doi: 10.7150/thno.23335. eCollection 2018.

20.

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.

Lobeek D, Franssen GM, Ma MT, Wester HJ, Decristoforo C, Oyen WJG, Boerman OC, Terry SYA, Rijpkema M.

J Nucl Med. 2018 Aug;59(8):1296-1301. doi: 10.2967/jnumed.117.206979. Epub 2018 Apr 6.

21.

The kinetics and mechanism of bone morphogenetic protein 2 release from calcium phosphate-based implant-coatings.

Liu Y, Schouten C, Boerman O, Wu G, Jansen JA, Hunziker EB.

J Biomed Mater Res A. 2018 Sep;106(9):2363-2371. doi: 10.1002/jbm.a.36398.

PMID:
29569828
22.

Characterization of 111In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors.

Willekens SMA, Joosten L, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2018 Feb 13;8(1):2948. doi: 10.1038/s41598-018-21259-3.

23.

Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.

van der Geest T, Roeleveld DM, Walgreen B, Helsen MM, Nayak TK, Klein C, Hegen M, Storm G, Metselaar JM, van den Berg WB, van der Kraan PM, Laverman P, Boerman OC, Koenders MI.

Rheumatology (Oxford). 2018 Apr 1;57(4):737-747. doi: 10.1093/rheumatology/kex456.

PMID:
29361119
24.

Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.

Tesselaar MH, Crezee T, Schuurmans I, Gerrits D, Nagarajah J, Boerman OC, van Engen-van Grunsven I, Smit JWA, Netea-Maier RT, Plantinga TS.

J Nucl Med. 2018 May;59(5):780-786. doi: 10.2967/jnumed.117.200675. Epub 2017 Dec 14.

25.

Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging.

Joosten L, Brom M, Peeters H, Heskamp S, Béhé M, Boerman O, Gotthardt M.

Mol Pharm. 2018 Feb 5;15(2):486-494. doi: 10.1021/acs.molpharmaceut.7b00853. Epub 2017 Dec 21.

26.

Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.

Lütje S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, Fracasso G, Colombatti M, Boerman OC, Heskamp S.

J Nucl Med. 2018 Mar;59(3):494-501. doi: 10.2967/jnumed.117.196279. Epub 2017 Nov 16.

27.

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.

Hekman MCH, Boerman OC, Bos DL, Massuger LFAG, Weil S, Grasso L, Rybinski KA, Oosterwijk E, Mulders PFA, Rijpkema M.

Mol Pharm. 2017 Oct 2;14(10):3457-3463. doi: 10.1021/acs.molpharmaceut.7b00464. Epub 2017 Aug 30.

28.

Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.

Huizing FJ, Hoeben BAW, Franssen G, Lok J, Heskamp S, Oosterwijk E, Boerman OC, Bussink J.

Radiother Oncol. 2017 Sep;124(3):521-525. doi: 10.1016/j.radonc.2017.07.025. Epub 2017 Aug 5.

PMID:
28789809
29.

Non-invasive in vivo determination of viable islet graft volume by 111In-exendin-3.

Eter WA, Van der Kroon I, Andralojc K, Buitinga M, Willekens SMA, Frielink C, Bos D, Joosten L, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2017 Aug 3;7(1):7232. doi: 10.1038/s41598-017-07815-3.

30.

89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.

Heskamp S, Raavé R, Boerman O, Rijpkema M, Goncalves V, Denat F.

Bioconjug Chem. 2017 Sep 20;28(9):2211-2223. doi: 10.1021/acs.bioconjchem.7b00325. Epub 2017 Aug 24. Review.

31.

Intraoperative Imaging Techniques to Support Complete Tumor Resection in Partial Nephrectomy.

Hekman MCH, Rijpkema M, Langenhuijsen JF, Boerman OC, Oosterwijk E, Mulders PFA.

Eur Urol Focus. 2018 Dec;4(6):960-968. doi: 10.1016/j.euf.2017.04.008. Epub 2017 May 12. Review.

PMID:
28753888
32.

Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination.

Cavina L, van der Born D, Klaren PHM, Feiters MC, Boerman OC, Rutjes FPJT.

European J Org Chem. 2017 Jun 30;2017(24):3387-3414. doi: 10.1002/ejoc.201601638. Epub 2017 Apr 26. Review.

33.

Perfluorocarbon/Gold Loading for Noninvasive in Vivo Assessment of Bone Fillers Using 19F Magnetic Resonance Imaging and Computed Tomography.

Mastrogiacomo S, Dou W, Koshkina O, Boerman OC, Jansen JA, Heerschap A, Srinivas M, Walboomers XF.

ACS Appl Mater Interfaces. 2017 Jul 12;9(27):22149-22159. doi: 10.1021/acsami.7b04075. Epub 2017 Jun 28.

34.

Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.

Joosten L, Brom M, Schäfer MKH, Boerman OC, Weihe E, Gotthardt M.

Sci Rep. 2017 May 11;7(1):1751. doi: 10.1038/s41598-017-01852-8.

35.

213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S.

Cancer Biother Radiopharm. 2017 Mar;32(2):67-73. doi: 10.1089/cbr.2016.2155.

PMID:
28301262
36.

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.

Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.

J Nucl Med. 2017 Jun;58(6):926-933. doi: 10.2967/jnumed.116.187021. Epub 2017 Feb 23.

37.

Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.

Nadar RA, Margiotta N, Iafisco M, van den Beucken JJJP, Boerman OC, Leeuwenburgh SCG.

Adv Healthc Mater. 2017 Apr;6(8). doi: 10.1002/adhm.201601119. Epub 2017 Feb 16. Review.

PMID:
28207199
38.

Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model.

Hekman MCH, Rijpkema M, Bos DL, Oosterwijk E, Goldenberg DM, Mulders PFA, Boerman OC.

J Nucl Med. 2017 May;58(5):706-710. doi: 10.2967/jnumed.116.185470. Epub 2017 Jan 26.

39.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

40.

Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents.

Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC.

Theranostics. 2017 Jan 1;7(1):1-8. doi: 10.7150/thno.15124. eCollection 2017.

41.

Quantitative and longitudinal imaging of intramuscular transplanted islets of Langerhans with SPECT using [ 123 I]IBZM.

Willekens SM, van der Kroon I, Bos D, Joosten L, Frielink C, Boerman OC, Brom M, Gotthardt M.

Diabetes Obes Metab. 2017 Apr;19(4):604-608. doi: 10.1111/dom.12857. Epub 2017 Jan 30.

PMID:
27987245
42.

Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca2+, FOS, and Autophagy-Dependent Pathways.

Tesselaar MH, Crezee T, Swarts HG, Gerrits D, Boerman OC, Koenderink JB, Stunnenberg HG, Netea MG, Smit JW, Netea-Maier RT, Plantinga TS.

Mol Cancer Ther. 2017 Jan;16(1):169-181. doi: 10.1158/1535-7163.MCT-16-0460. Epub 2016 Nov 11.

43.

Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.

Heskamp S, Heijmen L, Gerrits D, Molkenboer-Kuenen JDM, Ter Voert EGW, Heinzmann K, Honess DJ, Smith DM, Griffiths JR, Doblas S, Sinkus R, Laverman P, Oyen WJG, Heerschap A, Boerman OC.

Mol Imaging Biol. 2017 Aug;19(4):540-549. doi: 10.1007/s11307-016-1021-2.

44.

CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.

Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM, Boerman OC, Bakker LB, Jansen JH, Schaap N, Dolstra H, Hobo W.

J Immunol. 2016 Oct 1;197(7):2715-25. doi: 10.4049/jimmunol.1600011. Epub 2016 Aug 26.

45.

Improved Quantification of the Beta Cell Mass after Pancreas Visualization with 99mTc-demobesin-4 and Beta Cell Imaging with 111In-exendin-3 in Rodents.

van der Kroon I, Joosten L, Nock BA, Maina T, Boerman OC, Brom M, Gotthardt M.

Mol Pharm. 2016 Oct 3;13(10):3478-3483. Epub 2016 Aug 31.

PMID:
27537699
46.

The effect of purification of Ga-68-labeled exendin on in vivo distribution.

Brom M, Franssen GM, Joosten L, Gotthardt M, Boerman OC.

EJNMMI Res. 2016 Dec;6(1):65. doi: 10.1186/s13550-016-0221-8. Epub 2016 Aug 12.

47.

In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.

van der Meer LT, Terry SY, van Ingen Schenau DS, Andree KC, Franssen GM, Roeleveld DM, Metselaar JM, Reinheckel T, Hoogerbrugge PM, Boerman OC, van Leeuwen FN.

J Nucl Med. 2017 Feb;58(2):214-220. doi: 10.2967/jnumed.116.177741. Epub 2016 Aug 4.

48.

Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody.

van der Geest T, Laverman P, Gerrits D, Walgreen B, Helsen MM, Klein C, Nayak TK, Storm G, Metselaar JM, Koenders MI, Boerman OC.

J Nucl Med. 2017 Jan;58(1):151-155. doi: 10.2967/jnumed.116.177931. Epub 2016 Aug 4.

49.

Radionuclide imaging of liposomal drug delivery.

van der Geest T, Laverman P, Metselaar JM, Storm G, Boerman OC.

Expert Opin Drug Deliv. 2016 Sep;13(9):1231-42. doi: 10.1080/17425247.2016.1205584. Epub 2016 Jul 7. Review.

PMID:
27351233
50.

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M.

Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. eCollection 2016.

Supplemental Content

Loading ...
Support Center